Go Pro

STAAR Surgical (STAA) Stock Price, News & Analysis

STAAR Surgical logo
$20.60 +0.28 (+1.39%)
Closing price 03:59 PM Eastern
Extended Trading
$20.64 +0.03 (+0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About STAAR Surgical Stock (NASDAQ:STAA)

Advanced

Key Stats

Today's Range
$20.14
$21.03
50-Day Range
$20.32
$28.98
52-Week Range
$15.59
$35.87
Volume
582,131 shs
Average Volume
1.17 million shs
Market Capitalization
$1.03 billion
P/E Ratio
294.36
Dividend Yield
N/A
Price Target
$27.90
Consensus Rating
Hold

Company Overview

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

STAA MarketRank™: 

STAAR Surgical scored higher than 67% of companies evaluated by MarketBeat, and ranked 245th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    STAAR Surgical has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on no strong buy ratings, 2 buy ratings, 8 hold ratings, and 3 sell ratings.

  • Upside Potential

    STAAR Surgical has a consensus price target of $27.90, representing about 34.6% upside from its current price of $20.72.

  • Amount of Analyst Coverage

    STAAR Surgical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about STAAR Surgical's stock forecast and price target.
  • Earnings Growth

    Earnings for STAAR Surgical are expected to grow by 38.46% in the coming year, from $0.39 to $0.54 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of STAAR Surgical is 296.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.11.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of STAAR Surgical is 296.46, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.66.

  • Price to Book Value per Share Ratio

    STAAR Surgical has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about STAAR Surgical's valuation and earnings.
  • Percentage of Shares Shorted

    14.15% of the float of STAAR Surgical has been sold short.
  • Short Interest Ratio / Days to Cover

    STAAR Surgical has a short interest ratio ("days to cover") of 5.71.
  • Change versus previous month

    Short interest in STAAR Surgical has recently decreased by 2.90%, indicating that investor sentiment is improving.
  • Dividend Yield

    STAAR Surgical does not currently pay a dividend.

  • Dividend Growth

    STAAR Surgical does not have a long track record of dividend growth.

  • News Sentiment

    STAAR Surgical has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • Search Interest

    Only 1 people have searched for STAA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, STAAR Surgical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    39.90% of the stock of STAAR Surgical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.70% of the stock of STAAR Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about STAAR Surgical's insider trading history.
Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STAA Stock News Headlines

10% yields… from a gold security?
Most stocks yield under 2%. Even gold stocks average less than 1%. One gold security, backed by one of the world's best mines, is yielding upwards of 10%. The Rothschilds, Vanguard, and BlackRock have already taken positions. With at least 8 more years of production ahead, early investors could see substantial total returns as prices start to move.tc pixel
STAAR Surgical (STAA) Swings To Profit On China Rebound
STAAR Surgical hires former CEO to lead commercial team
Staar Surgical Reappoints David Bailey to Drive Growth
STAAR Surgical Appoints David Bailey as Chief Commercial Officer
See More Headlines

STAA Stock Analysis - Frequently Asked Questions

STAAR Surgical's stock was trading at $23.09 at the beginning of the year. Since then, STAA shares have decreased by 10.2% and is now trading at $20.7240.

STAAR Surgical Company (NASDAQ:STAA) posted its quarterly earnings results on Wednesday, August, 12th. The medical instruments supplier reported $0.39 EPS for the quarter, beating the consensus estimate of $0.22 by $0.17. The business's revenue for the quarter was up 111.1% on a year-over-year basis.
Read the conference call transcript
.

STAAR Surgical's Board of Directors approved a stock repurchase plan on Friday, May 16th 2025, which authorizes the company to buy back $30,000,000 in shares, according to EventVestor. This means that the company could purchase up to 3.2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's management believes its shares are undervalued.

The following companies are subsidiaries of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.

Top institutional shareholders of STAAR Surgical include American Capital Management Inc. (1.70%), Defender Capital LLC. (0.87%), Bank of New York Mellon Corp (0.46%) and Squarepoint Ops LLC (0.38%). Insiders that own company stock include Broadwood Partners, LP, Aimee S Weisner and Arthur C Butcher.
View institutional ownership trends
.

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that STAAR Surgical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Palo Alto Networks (PANW) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/12/2026
Today
9/22/2026
Next Earnings (Estimated)
11/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:STAA
CIK
718937
Employees
957
Year Founded
1982

Price Target and Rating

High Price Target
$37.00
Low Price Target
$13.00
Potential Upside/Downside
+34.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.92
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.07
Trailing P/E Ratio
296.26
Forward P/E Ratio
53.18
P/E Growth
N/A
Net Income
-$80.45 million
Net Margins
1.13%
Pretax Margin
5.12%
Return on Equity
9.05%
Return on Assets
6.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.66
Quick Ratio
4.03

Sales & Book Value

Annual Sales
$239.44 million
Price / Sales
4.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.92 per share
Price / Book
3.00

Miscellaneous

Outstanding Shares
50,140,000
Free Float
30,137,000
Market Cap
$1.04 billion
Optionable
Optionable
Beta
1.21

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:STAA) was last updated on 9/22/2026 by MarketBeat.com Staff.
From Our Partners